Double Blind Study of Melatonin Effects on the Sleep-wake Rhythm, Cognitive and Non-cognitive Functions in Alzheimer Type Dementia

Melatonin administration resulted in a 33.2% increase in mean sleep time for participants with Alzheimer type of dementia.

• Melatonin significantly prolonged sleep time at night (p=0.017) and decreased night activity (p=0.014) compared to placebo.
• No significant differences were observed in daytime sleep time or activity between the melatonin and placebo groups.
• Cognitive function, as measured by the Alzheimer's Disease Assessment Scale (ADAS), improved more in the melatonin group, with a mean change of -4.3 points compared to 0.3 points in the placebo group (p=0.017).
• Non-cognitive functions also showed greater improvement with melatonin, reflected by a mean change of -4.1 points in the melatonin group versus -0.8 points in the placebo group (p=0.002).
• Melatonin administration may offer benefits for managing sleep and cognitive functions in Alzheimer type of dementia, though effects on daytime activity were not significant.

AI simplified